FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Evaluation of a training course for general practitioners within the melanoma multimedia education programme of the Italian Melanoma Intergroup: a study protocol
692PDF: 440SUPPLEMENTARY MATERIAL: 101HTML: 8 -
34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo1|2, Bruna Dalmasso3, Maria Chiara Scaini4, Laura Cendron5, Monica Rodolfo6, Ilaria Mattavelli7, Elena Tamborini8, Francesca Collina9, Gerardo Ferrara, Gabriele Madonna10, Carlo Cota11, Elisa Melucci12, Stefania Tommasi13, Martina Ubaldi14, Roberta Depenni15, Andrea Carugno16, Riccardo Marconcini17, Laura Orgiano18, Maurizio Lombardo19, Simona Sola20, Cristina Pellegrini21, Francesca Castiglione22, Matteo Gasparotto5|23, Alireza Jorkesh5, Stefania Pellegrini4, Edoardo Raposio1, Andrea Boutros2, Enrica Teresa Tanda2, Michele Guida25, Pietro Quaglino26, Giuseppe Palmieri27, Daniela Massi22, Paolo Antonio Ascierto10, Mario Mandalà*28, Chiara Menin*4, Paola Ghiorzo*24, Lorenza Pastorino*24, for the Italian Melanoma Intergroup29 | 1Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; 2IRCCS Ospedale Policlinico San Martino, Genova; 3IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; 4Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; 5Department of Biology, University of Padua, Padua; 6Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 7Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 8Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 9Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; 10Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; 11Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; 12Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; 13Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; 14Unit of Medical Oncology, University of Perugia; 15Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; 16Department of Medicine and Surgery, University of Insubria, Varese; 17Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; 18Department of Medical Oncology, University of Cagliari, Cagliari; 19Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; 20Surgical Pathology, Galliera Hospital, Genoa; 21Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; 22Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; 23Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 24Department of Internal Medicine and Medical Specialties, University of Genoa; 25Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; 26Dermatology Clinic, Department of Medical Sciences, University of Turin; 27Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; 28University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; 29Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.
296 -
20 | How Covid-19 pandemic influenced the diagnosis of new primary melanoma: a retrospective, multicenter study by the Italian Society of Oncological Surgery Giuseppe Sciacca*1|2, Luca Nespoli1, Virginia Caliendo2, Dario Piazzalunga3, Piero Rossi4, Marco Clementi5, Corrado Caracò6, Salvatore Asero7, Matteo Mascherini8, Franco De Cian8, Francesco Russano9, Paolo Del Fiore9, Sara Coppola10, Elisabetta Pennacchioli10, Pietro Gallina11, Marzia Franzò12, Marco Rastrelli9|12 | 1General and Emergency Surgery, School of Medicine and Surgery, Milano-Bicocca University, Fondazione IRCCS San Gerardo dei Tintori, Monza; 2Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin; 3Unit of Surgery, Papa Giovanni XXIII Hospital, Bergamo; 4Dipartimento Di Scienze Chirurgiche, Università di Roma Tor Vergata, Policlinico Tor Vergata, Rome; 5General Surgical Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 6Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori "Fondazione Pascale" IRCCS, Napoli; 7Soft Tissue U.O. Surgical Oncology-Soft Tissue Tumors, Dipartimento di Oncologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania; 8Department of Surgical Sciences and Integrated Diagnostic DISC, University of Genoa; 9Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova; 10Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milano; 11Directorate General, Veneto Institute of Oncology IOV-IRCCS, Padua; 12Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, AOPD Azienda Ospedale Università Padova, Padova, Italy.
312 -
23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*1, Teresa Amaral*2, Piotr Rutkowski*3, Marie-Lena Rasch2, Naima Benannoune4, Patricio Serra5, Maria Grazia Vitale6, Diana Giannarelli7, Ana Maria Arance8, Eva Munoz Couselo9, Bart Neyns10, Iris Dirven11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele Del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan5, Caroline Robert24, Georgina V. Long22, Paolo A. Ascierto6, Mario Mandalà25 | 1Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; 2Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Gustave Roussy Cancer Campus, Villejuif, France. 5The University of Manchester, Manchester, UK. 6Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; 7Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 8Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; 9Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; 10Department of Medical Oncology, UZ Brussel, Brussels, Belgium. 11Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; 12Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. 13Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. 14IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; 15Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 16IEO European Institute of Oncology, IRCCS, Milan, Italy. 17Department of Dermatology, University of Turin, Turin, Italy. 18University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; 19Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. 20Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 21Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; 22Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; 23Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 24Gustave Roussy and Paris-Saclay University, Villejuif, France; 25Unit of Medical Oncology, University of Perugia, Perugia, Italy. § on behalf of the Italian Melanoma Intergroup - IMI.
271 -
29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients Cristina Catoni1, Cristina Poggiana1, Alessandro Francesco Piazza1, Jacopo Pigozzo2, Luisa Piccin2, Chiara Menin1, Stefania Pellegrini1, Valentina Salizzato2, Paolo Del Fiore4, Simone Mocellin3|4, Vanna Chiarion-Sileni2, Valentina Guarneri2|3, Antonio Rosato1|3, Maria Chiara Scaini1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 2Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 3Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
266 -
06 | SUNTEL program: first experience of school integration of the ugly duckling sign with e-learning and peer education for melanoma awareness Giorgia Ravaglia1, Serena Magi2, Elisabetta Costa3, Matelda Medri2, Franca Gentilini4, Chiara Scutellà4, Daniela De Zerbi5, Silvia Gerosa1, Federica Zamagni6, Chiara Doccioli7, Sara Gandini8, Maria Costanza Cipullo9, Saverio Caini7, Ignazio Stanganelli1|2 | 1Dermatology Resident Training Program, Department of Medicine and Surgery, University of Parma, Parma; 2Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST Meldola, Forlì-Cesena; 3Graphic Design and Multimedia "Good Sun Good Skin" project, Istituto Oncologico Romagnolo, Forlì; 4IOR Scuola, Istituto Oncologico Romagnolo, Forlì; 5Scientific High School "Alfredo Oriani", Ravenna; 6Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS IRST Romagnolo Institute for the Study of Tumors "Dino Amadori", Meldola, Forlì-Cesena; 7Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention, and Clinical Network, ISPRO, Florence; 8Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan; 9Directorate General for Student Affairs, Inclusion, and Career Guidance, Prevention and Health Education Unit, Ministry of Education, Rome, Italy.
314 -
Dermatology Reports: a journal coming to a new life
750PDF: 367HTML: 8 -
04 | Association of a novel TERT polymorphism with poorer survival in male patients with melanoma Fortunato Cassalia1, Maria Santa Rocca2, Andrea Di Nisio3, Paolo del Fiore*4, Clara Benna5|7, Ilaria Cosci6, Simone Mocellin4|5, Alberto Ferlin*2|6 | 1Department of Dermatology, University of Padua, Padua; 2Unit of Andrology and Reproductive Medicine, University Hospital of Padua, Padua; 3Department of Wellbeing, Nutrition and Sport, Pegaso Telematic University, Naples; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 5Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 6Department of Medicine, University of Padua, Padua; 7Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
325 -
05 | Revisiting cancer risk associated with the MITF p.e318k variant beyond melanoma Debora Tonello1, Beatrice Zennaro1, Stefania Pellegrini1, Monica Quaggio2, Luisa Piccin3, Alessio Fabozzi4, Luigi Dall’Olmo2|5, Saveria Tropea5, Maria Chiara Scaini1, Chiara Menin1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova; 2Department of Surgery, Oncology and Gastroenterology, Section of Immunology and Oncology, AIDS Reference Center, University of Padova, Padova; 3Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova; 4Oncology Unit 3, Veneto Institute of Oncology - IOV-IRCCS, Padua; 5Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
305 -
36 | Neoadjuvant strategy for locally advanced conjunctival melanoma: a single-center approach to eye preservation F. Rifaldi1|2, M. Angi3, L. Giuseppe1, F. Lanza3, A. Spagnoletti1, J. Sergenti3, A. Indini1, E. Mastrogiuseppe3, M. Del Vecchio1, L. Di Guardo1 | 1Melanoma Medical Oncology Unit, Department of Medical Oncology ed Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 2Fondazione IRCCS Policlinico San Matteo, Pavia; 3Ocular Oncology Service, Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
355 -
13 | Spatial contexture of tertiary lymphoid structures as a predictor of recurrence in early-stage melanoma Chiara Bungaro1, Sabino Strippoli1, Daniele Carenza1, Ivana De Risi1, Rossella Villani1, Teresa Squicciarini1, Anna Albano1, Ileana De Roma1, Fabio Mele 2, Margherita Sonnessa2, Concetta Saponaro2, Francesco Alfredo Zito2, Arianna Bozzi3, Benedetta Apollonio1, Raffaella Massafra3, Michele Guida1 | 1Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 2Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 3Biostatistics and Bioinformatics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
317 -
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
304 -
01 | End-of-life care in advanced melanoma and other skin cancers: a retrospective cohort from an Italian comprehensive cancer center Michela De Mattia1, Enrica Teresa Tanda3, Andrea Boutros2, Virginia Delucchi5, Eva Blondeaux5, Agostina Lagodin D’Amato1, Irene Giannubilo1, Lucia Del Mastro1|2, Paolo Pronzato3, Francesco Spagnolo3|4, Claudia Bighin3 | 1Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova; 2U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova; 3U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova; 4Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate, Università di Genova, Genova; 5U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
416 -
07 | Early diagnosis of melanoma in the era of non-invasive imaging: histopathological confirmation of malignancy vs. clinical suspicion. a retrospective study of 2240 patients Giovanni Cecchi1, Gabriella Perillo1, Federica Fazzari1, Virginia Marabini2, Biancamaria Zuccaro1, Vincenzo De Giorgi1 | 1Dipartimento di Scienze della Salute, Sezione di Dermatologia, Università di Firenze; 2Dipartimento di Scienze della Salute, Università di Firenze, Italy.
289 -
16 | Sentinel lymph node biopsy in elderly patients with melanoma: prognostic value and impact on recurrence B. Taglione1, I. Mattavelli1, A. Maurichi1, G. Gallino1, D. Cortese1, A. Manfredi1, S. Mercurio1, G. Spadola1, E. Tolomio1, C. Barbieri1, B. Scoppio1, M. Cossa2, B. Valeri2, M. Santinami1, R. Patuzzo1 | 1IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Melanoma Surgical Unit, Milano; 2IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Pathology, Milano, Italy.
287 -
21 | Melanoma in situ: long-term outcomes and follow-up strategies based on risk stratification Beatrice De Checchi1, Paolo del Fiore2, Irene Russo2, Chiara Trevisiol2, Marco Domenico Mazza2, Saveria Tropea2, Francesco Russano2, Mauro Alaibac3, Carlomaria Gianesini4, Giovanni Madeo4, Simone Mocellin2|4 | 1Department of Medicine, University of Padua, Padua; 2Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 3Department of Dermatology, University of Padua; 4Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
291 -
08 | Cutaneous melanoma and occupational UV exposure: associations with anatomical site, histological subtype, and Breslow thickness Federica Fazzari, Giovanni Cecchi, Gabriella Perill, Biancamaria Zuccaro, Vincenzo De Giorgi | Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
310 -
18 | Surgical management of pregnancy-associated melanoma: a single institution experience with thirty-three pregnant patients B. Taglione1, I. Mattavelli1, A. Maurichi1, G. Gallino1, D. Cortese1, E. Tolomio1, G. Spadola1, C. Barbieri1, S. Mercurio1, B. Scoppio1, B. Valeri2, M. Cossa2, M. Maccauro3, L. Di Guardo4, M. Del Vecchio4, M. Santinami1, R. Patuzzo1 | 1IRCCS Istituto Nazionale Tumori Milano, Surgery, Milano; 2IRCCS Istituto Nazionale Tumori Milano, Pathology, Milano; 3IRCCS Istituto Nazionale Tumori Milano, Nuclear Medicine, Milano; 4IRCCS Istituto Nazionale Tumori Milano, Medical Oncology, Milano, Italy.
316 -
09 | Integration of hematoxylin and eosin and immunohistochemistry images to improve AI-based recurrence prediction in negative sentinel lymphnode melanoma patients Maria Colomba Comes1, Andrea Lupo1, Fabio Mele2, Concetta Saponaro2, Arianna Bozzi1, Ivana De Risi3, Samantha Bove1, Annarita Fanizzi1, Benedetta Apollonio3, Margherita Sonnessa2, Sabino Strippoli3, Francesco Alfredo Zito2, Michele Guida3, Raffaella Massafra1 | 1Biostatistics and Bioinformatics Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 2Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 3Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
298
